| **Virginia Department of Health| Long-Term Care Facility Task Force Monthly Updates| August 2022**

| Text, logo  Description automatically generated**Long-Term Care Facility Task Force** **Monthly Updates****COVID-19 Burden in Virginia LTCF**There were 85 LTCF COVID-19 outbreaks reported in the past 30 days (as of 08/31). This is similar to the number of outbreaks reported (71) in the previous month (07/31 - 08/31). The number of reported nursing home resident and staff cases and hospitalizations have been slightly on the decline.**EVUSHELD Access Program Pilot****EVUSHELD Mobile Unit**Plans to launch in the Central Region by mid-to-late September; hope to expand to remaining regions and other facility types in the future. Currently 10 SNFs committed to taking part in the program and 15 interested.If you are interested in bringing the EVUSHELD Mobile Unit to your facility please fill out [EVUSHELD Access Interest Form](https://redcap.link/EVUSHELDAccessInterestForm) Reach out to COVID19Therapeutics@vdh.virginia.gov for questions, comments, or feedback on information you’d like to see. For information on Therapeutics, go to the COVID-19 Virginia Therapeutics website [here](https://www.vdh.virginia.gov/coronavirus/get-the-latest-guidance/health-professionals/therapeutics/) . **COVID-19 Therapeutics Utilization in Nursing Homes****Bebtelovimab is Available for Purchase Commercially** As of August 17, 2022, Bebtelovimab has become commercially available for purchase. Orders can be placed directly through AmerisourceBergen. USG will allocate the remaining supply of Bebtelovimab to jurisdictions based on populations on September 6, 2022. Providers should not bill patients or insurance for any USG-procured product. HHS & VDH place a high priority on equitable availability of product. If a facility does not serve the under and/or uninsured, VDH encourages these locations to utilize the redistribution process to reallocate USG product for this vulnerable population. USG supply and administration of Bebtelovimab will still need to be reported in HPoPIf you would like to redistribute some of your USG Bebtelovimab, please fill out the redistribution survey [Redistribution Survey](https://redcap.vdh.virginia.gov/redcap/surveys/?s=XT4WFMD979) **Virginia Healthcare Emergency Management Program Updates**Through a partnership between VDH and the Virginia Hospital &amp; Healthcare Association (VHHA)the Virginia Healthcare Emergency Management Program was created to help enhance Virginia’shealth care system capabilities to respond and recover from a wide range of public health andhealthcare emergencies. The VHEMP maintains and consists of six healthcare coalitions (HCCs).HCCs bring together individual health care and response organizations, such as acute care hospitals,emergency medical service (EMS) providers, emergency management, public health, and long term carepartners to prepare and respond to emergencies and disasters. HCC members actively participate inregional strategic planning, operational planning, information sharing, resource coordination andmanagement, and provide regional training and exercise opportunities. Additionally, (HCC) serve as acommunication and coordination role within their respective regions via the Regional HealthcareCoordinating Center (RHCC).If you are interested in additional information or would like to become a member of your respectiveHealthcare Coalition, please click the link below for additional information and contact information.<https://www.vdh.virginia.gov/emergency-preparedness/hospital-healthcare-preparedness/>**COVID-19 Vaccine Update****COVID-19 Fall Booster Vaccines**On June 30, 2022, the U.S. Food and Drug Administration (FDA) advised vaccine manufacturers seeking to update their COVID-19 vaccines to add an Omicron BA.4/5 spike protein component to the current vaccine composition to create a bivalent booster vaccine. Pending potential FDA Emergency Use Authorizations (EUAs) for new bivalent COVID-19 boosters developed by Pfizer-BioNTech and Moderna in September 2022, CDC’s Advisory Committee on Immunization Practices (ACIP) will convene to discuss potential recommendations. Anticipated EUA is around Labor Day weekend. Administration of any new bivalent COVID-19 boosters can begin only after CDC’s official recommendations. The bivalent COVID-19 vaccine will be administered as a single booster dose to those who previously completed a primary series of COVID-19 vaccine. It is anticipated that bivalent COVID-19 vaccine booster doses may initially be authorized for people ages 12 years and older (Pfizer-BioNTech) and for people ages 18 years and older (Moderna), followed by younger pediatric age groups. It is also anticipated that the bivalent COVID-19 vaccines **will only be authorized as a single dose in people who have completed a primary vaccination series but would not vary by number or type of prior booster doses received**. The new vaccines will have the same storage and handling parameters as the original vaccine products. **Newly Authorized COVID-19 vaccine, Novavax**Novavax COVID-19 vaccine is under EUA for adults 18 years and older. It is given as a 2 dose primary series, separated by 3-8 weeks. People who are moderately or severely immunocompromised should also receive 2 doses, given 3 weeks apart (a 3rd primary dose is not currently authorized). Novavax COVID-19 vaccine is **not currently authorized for use as a booster dose, ONLY as a primary series**. For more information about the Novavax COVID-19 vaccine, visit [CDC COVID-19 Vaccine page](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/novavax.html). **VDH Team Contact Information*** Testing:  testinginfo@vdh.virginia.gov
* Vaccination:  covidpharmacysupport@vdh.virginia.gov
* Therapeutics:  covid19therapeutics@vdh.virginia.gov
* Infection Prevention and Control:  hai@vdh.virginia.gov

**Have any important updates or information for the Virginia Department of Health’s Long-Term Care Task Force? Email Jessica Caggiano (****jessica.caggiano@vdh.virginia.gov****)** Text, logo  Description automatically generated |
| --- |

 |
| --- | --- |
|  |